

1 **Cardiac Abnormalities in Hispanic Women with Prior**
2 **De Novo Hypertensive Disorders of Pregnancy**

3
4 Odayme Quesada, MD,^{a,b} Shathiyah Kulandavelu, PhD,^c Catherine J. Vladutiu, PhD, MPH,^d
5 Emily DeFranco, DO, MS,^e Margo B. Minissian, PhD^f Nour Makarem, PhD,^g Natalie A. Bello,
6 MD, MPH,^c Melissa S. Wong, MD,^h Maria Pabón, MD,ⁱ Alvin A. Chandra, MD,^j Larissa Avilés-
7 Santa, MD, MPH,^k Carlos J. Rodríguez, MD,^l C. Noel Bairey Merz, MD,^{c,m} Tamar Sofer, PhD,ⁿ
8 Barry E Hurwitz, PhD,^o Gregory A. Talavera, MD, MPH,^p Brian L. Claggett, PhDⁱ Scott D.
9 Solomon, MD,ⁱ Susan Cheng, MD, MPH^c

10
11
12 ^aWomen's Heart Center, The Christ Hospital Heart and Vascular Institute, Cincinnati, OH; ^b The
13 Carl and Edyth Lindner Center for Research and Education, The Christ Hospital, Cincinnati, OH;
14 ^cDepartment of Pediatrics, Miller School of Medicine, Miami, FL; ^dDepartment of Obstetrics and
15 Gynecology, University of North Carolina, Chapel Hill, NC; ^eDivision of Maternal Fetal Medicine,
16 Department of Obstetrics and Gynecology, University of Cincinnati, Cincinnati, OH; ^fBrawerman
17 Nursing Institute, Cedars-Sinai Medical Center, Los Angeles, CA; ^gMialman School of Public
18 Health, Columbia University Irving Center, NY, NY; ^hDivision of Maternal Fetal Medicine,
19 Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA;
20 ⁱDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School,
21 Boston, MA; ^jUniversity of Texas Southwestern Medical Center, Dallas, TX; ^kNational Institute
22 on Minority Health and Health Disparities, Bethesda, MD; ^lAlbert Einstein College of Medicine,
23 Bronx, NY; ^mBarbra Streisand Women's Heart Center; ⁿDepartment of Medicine, Brigham and
24 Women's Hospital, Harvard Medical School, Boston, MA; ^oDepartment of Psychology, University
25 of Miami, Miami, FL. ^pSouth Bay Latino Research Center, Department of Psychology, San
26 Diego State University, San Diego, CA.

27

28 **Short Title: Cardiac Abnormalities in Women with HDP**

29

30 **Address for Correspondence:**

31 Odayme Quesada, MD, Women's Heart Center, The Christ Hospital Heart, Vascular, and Lung

32 Institute, Cincinnati, OH, phone 513-585-1777, email odayme.quesada@thechristhospital.com,

33 Twitter: @OdaymeMD; and Susan Cheng, MD, MPH, Department of Cardiology, Smidt Heart

34 Institute, Cedars Sinai Medical Center

35

36 **Word count: 6,979**

37

38

39

40 **ABSTRACT**

41 **Background.** Hypertensive disorders of pregnancy (HDP) are associated with longer-term
42 maternal risks for cardiovascular disease for reasons that remain incompletely understood.

43 **Methods.** The Hispanic Community Health Study/Study of Latinos (HCHS/SOL), a multi-center
44 community-based cohort of Hispanic/Latino adults recruited 2008 to 2011 was used to evaluate
45 the associations of history of de novo HDP (gestational hypertension, preeclampsia, eclampsia)
46 with echocardiographic measures of left ventricular (LV) structure and function in
47 Hispanic/Latina women with ≥ 1 prior pregnancy and the proportion of association mediated by
48 current hypertension.

49 **Results.** The study cohort included 5,168 Hispanic/Latina women. Prior de novo HDP was
50 reported by 724 (14%) of the women studied with an average age of 58.7 ± 9.7 years at time of
51 echocardiogram and was associated with lower ejection fraction -0.66 ($-1.21, -0.11$), greater
52 relative wall thickness (RWT) 0.09 ($0, 0.18$), and 1.39 ($1.02, 1.89$) greater odds of abnormal LV
53 geometry after adjusting for blood pressure and other risk factors. The proportion of association
54 mediated by current hypertension between HDP and LV ejection fraction was 0.09 (95% CI
55 $0.03, 0.45$), any abnormal LV geometry was 0.14 ($0.12, 0.48$), LV RWT 0.28 ($0.16, 0.51$),
56 concentric LVH was 0.31 ($0.19, 0.86$), and abnormal LV diastolic dysfunction was 0.58 ($0.26,$
57 1.79).

58 **Conclusions.** In a large cohort of Hispanic/Latina women those with de novo HDP had
59 detectable and measurable subclinical alterations in cardiac structure and both systolic and
60 diastolic dysfunction that were only partially mediated by current hypertension.

61
62

63 **KEY WORDS**

64 Hypertensive disorders of pregnancy, women cardiovascular risk, left ventricular geometry,
65 diastolic dysfunction, systolic dysfunction

66

67 **ABBREVIATIONS**

68 BP: blood pressure

69 CVD: Cardiovascular disease

70 HCHS/SOL: Hispanic Community Health Study/Study of Latinos

71 HDP: Hypertensive disorders of pregnancy

72 LV: Left ventricle

73 LVH: Left ventricular hypertrophy

74 RWT: Relative wall thickness

75 TTE: Transthoracic echocardiography

76

77 INTRODUCTION

78 The rates of hypertensive disorders of pregnancy (HDP), including preeclampsia and
79 gestational hypertension, more than doubled from 2007 to 2019 in the United States (U.S.) with
80 highest rates in Non-Hispanic Black and Hispanic/Latina women.^{1,2} Growing evidence
81 demonstrates that history of HDP is associated with higher maternal risk for long-term
82 cardiovascular disease (CVD) and CVD-related death; resulting in the addition of HPDs as risk-
83 modifiers in the 2019 American College of Cardiology/ American Heart Association (ACC/AHA)
84 primary prevention guidelines.³⁻⁸

85
86 Prior investigations have found evidence of structural cardiac abnormalities during the
87 antepartum and immediate postpartum period, attributable in part to the short-term
88 hemodynamic effects of pregnancy due to the stress of excess afterload.⁹⁻¹² These cardiac
89 structural changes, including increased left ventricular (LV) wall thickness, LV mass index,
90 diastolic dysfunction and abnormalities in right ventricular (RV) strain, have been shown to
91 persist postpartum.^{11,13,14} However, the role of chronic hypertension on these changes remains
92 debatable.

93
94 Up to 20% of women with pregnancies complicated by HDP remain hypertensive after 6 months
95 postpartum and have a 4-fold lifetime risk of chronic hypertension.¹⁵⁻¹⁷ Some studies show that
96 adverse remodeling is driven by chronic hypertension regardless of HDP-history,^{11,13} whereas
97 others demonstrate adverse remodeling associated with HDP is independent of development of
98 chronic hypertension and a cumulative effect in those with both history of HDP and subsequent
99 chronic hypertension.¹⁴ However, very little is known about the effects of HDP on cardiac
100 abnormalities and the role of chronic hypertension in Hispanic/Latina women, one of the
101 fastest-growing ethnic minority group in the U.S. with a diverse and broadly representative
102 genetic architecture.¹⁸

103
104 The degree to which any important cardiac abnormalities occur well beyond the early
105 postpartum period prior to the development of CVD decades later– notwithstanding the effects
106 of postpartum or age-related chronic hypertension – has remained unclear. We hypothesize that
107 history of de novo HDP is associated with pathologic alterations in cardiac structure and
108 function that are only partially mediated by current hypertension. We aimed to examine this
109 hypothesis in a diverse cohort of Hispanic/Latina women in the U.S.

110
111
112 **METHODS**
113

114 **Study Sample**

115 We studied participants of the Hispanic Community Health Study/Study of Latinos (HCHS/SOL),
116 a multi-center community-based cohort of all Hispanic/Latino adults representing diverse
117 backgrounds (Central American, Cuban, Dominican, Mexican, Puerto Rican, and South
118 American).¹⁸ The HCHS/SOL sampling methods and design have been detailed previously.^{19,20}
119 In brief, self-identified Hispanic/Latino men and women were recruited between March 2008 to
120 June 2011 from 4 communities in the United States (Bronx, NY; Chicago, IL; Miami, FL; and
121 San Diego, CA) using a multi-stage area probability sample design. At each stage of sampling,
122 oversampling occurred, and sampling weights were generated to reflect the probabilities of
123 selection. The institutional review board at each study site approved all protocols, and all study
124 participants provided written informed consent. Data from the HCHS/SOL cohort is publicly
125 available to researchers upon application to NHLBI BIOLINCC.

126
127 Of the 16,415 HCHS/SOL participants who enrolled in this study, we included women age ≥ 45
128 years who completed visit 2 and transthoracic echocardiography (TTE) and reported at least 1
129 prior pregnancy at baseline visit (2008-2011) or visit 2 (2014-2017). We excluded men

130 (n=4,281), participants that did not complete visit 2 (n=4,792), did not complete echocardiogram
131 (n=1,663), participants that were never pregnant or missing data on pregnancy history (n=405),
132 and participants with missing data on HDP history (n=109). The final sample for this analysis
133 included 5,168 women (724 with HDP and 4444 without HDP) (**Figure 1**).

134

135 **Clinical and Echocardiographic Data Collection**

136 At each study visit, all study participants underwent a standardized assessment of demographic
137 and clinical characteristics including questionnaires regarding medical and pregnancy history
138 along with standardized measurements of blood pressure (BP), as previously described.²⁰⁻²² All
139 participants included had self-reported data on the history of gestational hypertension,
140 preeclampsia and eclampsia for all their pregnancies collected through questionnaires at visit 1
141 and 2. We defined composite HDP status as any history of de novo gestational hypertension,
142 preeclampsia, or eclampsia.

143

144 At visit 2, participants age ≥ 45 years underwent comprehensive 2D TTE performed according to
145 a previously detailed standardized protocol.²³ In brief, TTE examination was performed with the
146 participant in the partial left decubitus position with image acquisition techniques and
147 measurements of cardiac structure and function performed according to American Society of
148 Echocardiography guidelines.^{24,25} All image acquisition was performed by centrally trained and
149 certified research sonographers and all imaging measurements were conducted by imaging
150 technical specialists at the core HCHS/SOL Echocardiography Reading Center at Brigham and
151 Women's Hospital.²³

152

153 As previously described, we defined concentric remodeling as LV mass index ≤ 95 gm/m² and
154 RWT > 0.42 , concentric LVH as LV mass index > 95 gm/m² and RWT > 0.42 , and eccentric LVH
155 as LV mass index > 95 gm/m² and RWT ≤ 0.42 .²⁴ Any abnormal LV geometry was defined as

156 presence of concentric remodeling, concentric LVH or eccentric LVH. Diastolic function was
157 graded according to an algorithm that integrates American Society of Echocardiography (ASE)
158 guidelines²⁶ with Redfield criteria²⁷ as previously described.^{21,28} In the analysis, LV diastolic
159 dysfunction was dichotomized and grade I-IV diastolic dysfunction was compared to normal
160 diastolic function.

161

162 **Statistical Analyses**

163 We compared demographic, clinical, and echocardiographic traits in women with and without
164 prior HDP using the Student's t-test for continuous variables and Chi-square test for categorical
165 variables. Holm-Bonferroni method was used to adjust for multiple comparisons. We then used
166 multivariable-adjusted regression models to examine the association of prior HDP status with
167 established measures of LV structure and function: LV ejection fraction, LV stroke volume, LV
168 mass index, LV end-diastolic diameter, LV mass/end-diastolic volume ratio, LV relative wall
169 thickness (RWT), peak tricuspid regurgitation velocity, lateral E/e' ratio, abnormal LV geometry
170 and LV diastolic function. We constructed linear and logistic regression models for continuous
171 and categorical variables, respectively. For all echocardiographic traits, model 1 adjusted for
172 age, study field center, and Hispanic/Latino background. Model 2 adjusted for the covariates in
173 model 1, in addition to SBP and treatment with antihypertensive therapy at the time of TTE (Visit
174 2). Model 3 adjusted for the covariates in model 2, in addition to body mass index, diabetes,
175 smoking, total number of prior pregnancies, total cholesterol/HDL ratio, and urine albumin-to-
176 creatinine ratio all assessed at the time of TTE. Covariates were selected based on prior studies
177 demonstrating association with HDP and/or LV measures of structure/function.^{11,13,14} No
178 adjustments were made for multiple testing. Stratified analyses were performed by type of HDP
179 for gestational hypertension and preeclampsia, however the sample size was too small to
180 perform adjusted models for eclampsia. Reported values were survey-weighted, to account for

181 the complex study design and the non-responses for visit 2.¹⁹ Weights were trimmed and
182 calibrated to the 2010 Census characteristics by age, sex, and Hispanic/Latino background.
183 In secondary analyses, we examined the extent to which current hypertension mediated the
184 associations of HDP with echocardiography traits. Models are adjusted for age, field center,
185 Hispanic/Latin background, and current hypertension stage 2 (defined as BP >140/90 mmHg or
186 antihypertensive therapy). These analyses test the extent to which current hypertension mediate
187 the associations of HDP with the given echocardiographic trait, whereby a mediation effect of 0
188 would indicate that current hypertension does not mediate the association and a mediation
189 effect of 1 would indicate that current hypertension mediates all of the association (range of
190 possible effect is from 0 to 1). We also assessed for potential interaction of current hypertension
191 on HDP associations with each of the echocardiographic traits.

192
193 We considered statistical significance as a two-tailed P value and Holm-Bonferroni adjusted P
194 value of less than 0.05. All statistical analysis were conducted using R (v4.0.4).

195 196 **RESULTS** 197

198 Of the total study sample including 5,168 women with prior pregnancy, 724 (14%) reported a
199 history of de novo HDP including 439 (61%) gestational hypertension, 219 (30%) preeclampsia,
200 and 66 (9%) eclampsia. The mean age at the time of examination and TTE was 58.7±9.7 years.
201 The demographic and clinical characteristics of the study sample at visit 2 are shown in **Table 1**.
202 Women with a history of HDP, compared to those without HDP were younger, had a higher level
203 of education, greater body mass index, and more frequent dyslipidemia. After the Holm-
204 Bonferroni adjustment, dyslipidemia and HDL-cholesterol levels were no longer statistically
205 different between the groups. With respect to echocardiographic LV characteristics (**Table 2**),
206 women with prior HDP had lower LV ejection fraction, higher LV stroke volume, greater LV

207 mass index, greater LV RWT, and higher peak tricuspid regurgitation velocity (PTRV).

208 Accordingly, HDP was also associated with greater concentric LVH, presence of any abnormal
209 LV geometry, and presence of abnormal diastolic function. After the Holm-Bonferroni
210 adjustment, LV mass index and PTRV were not significantly different between the groups.

211
212 In multivariable-adjusted analyses of the continuous LV structure and function measures, prior
213 HDP was associated with lower LV ejection fraction in all models including adjustment for
214 systolic BP, antihypertensive therapy and traditional risk factors ($P \leq 0.02$) (**Table 3**). Prior HDP
215 was also associated with increased LV RWT in all models ($P \leq 0.039$). Accordingly, among the
216 categorical LV measures, prior HDP was associated with presence of concentric LVH in model
217 1 adjusted for age and demographic factors ($P = 0.001$), but the association was attenuated in
218 analyses adjusting for systolic BP and antihypertensive therapy ($P = 0.07$). Notably, prior HDP
219 was significantly associated with presence of any abnormal LV geometry in all models
220 ($P \leq 0.038$). In addition, prior HDP was associated with presence of abnormal LV diastolic
221 function in models adjusting for age and demographic factors ($P = 0.006$); this association was
222 attenuated in analyses adjusting for systolic BP and antihypertensive therapy ($P = 0.43$). All other
223 measures of LV structure and function were nonsignificant.

224
225 In secondary analyses, we examined the extent to which current hypertension mediated the
226 associations of HDP with echocardiography traits. We found that the proportion of association
227 between HDP and LV ejection fraction that was mediated by current hypertension was modest
228 at 0.09 (95% CI 0.03, 0.45), with similar results seen for any abnormal LV geometry (0.14 [0.12,
229 0.48]). The proportions of association between HDP and other traits such as LV RWT (0.28
230 [0.16, 0.51]), concentric LVH (0.31 [0.19, 0.86]), and abnormal LV diastolic dysfunction (0.58
231 [0.26, 1.79]) that were mediated by postpartum hypertension were higher, as expected given
232 results of multivariable-adjusted models described above (**Table 4**). We also assessed for

233 potential interaction of current hypertension on HDP associations with each of the
234 echocardiographic traits and found no significant interactions ($P>0.30$ for all). We observed no
235 material difference in any results of analyzing data using survey-weighted versus unweighted
236 values.

237
238 In stratified analysis by type of HDP, there was a trend towards lowest ejection fraction and LV
239 stroke volume and highest LV RWT in women with eclampsia history (**Supplemental Table 1**).
240 The presence of concentric LVH was highest in women with history of gestational hypertension
241 and presence of abnormal LV diastolic function was highest in those with history of
242 preeclampsia and gestational hypertension. In multivariable-adjusted analyses, gestational
243 hypertension was associated with LV RWT and 1.79-fold higher risk of abnormal LV geometry
244 across all models, whereas there was no association between preeclampsia and any of the
245 measures of LV structure and function (**Supplemental Table 2**).

246

247 **DISCUSSION**

248

249 In our study of over 5,100 Hispanic/Latina women with prior pregnancy, 14% reported de novo
250 HDP. Women with history of de novo HDP were significantly more likely to have measurable
251 abnormalities in cardiac structure and function, including lower LV systolic function and higher
252 rates of abnormal LV geometry than women without history of HDP. These cardiac alterations
253 were in part mediated by the effects of current hypertension (**Central Illustration**).

254

255 The rate of de novo HDP in this study is consistent with the U.S. National Inpatient Sample
256 between 2017 and 2019 which reported 12.5% (95% CI 12.2-12.8).²⁹ To date, a scant number
257 of studies have examined cardiac phenotypes up to a decade or longer following delivery prior
258 to development of clinical CVD; these few studies, each involving sample sizes of less than 200

259 women with history of HDP, have found evidence of LVH or diastolic dysfunction.^{30,31} In studies
260 accounting for chronic hypertension, findings have also been mixed on whether or not the
261 changes in LV structure and function associated with HDP history are present after adjusting for
262 chronic hypertension – an obvious potentially confounding contributor to subsequent cardiac
263 risk.^{11,13,14} We extend previous work and analyze one of the largest samples of de novo HDP in
264 724 women and compared their cardiac phenotypes with 4444 similarly aged clinical controls
265 (i.e. women with prior pregnancy but no HDP). Importantly, we found that prior HDP was
266 associated with higher LV RWT and abnormal LV geometry – even after adjusting for current
267 hypertension and CV risk factors – consistent with a recent study by Countouris et al.¹⁴ in a
268 cohort of NHW and Black women. Our study extends these findings to Hispanic/Latina women
269 who are underrepresented in research studies.

270

271 In this study history of pregnancy complicated by de novo HDP was associated with higher risk
272 of abnormal LV geometry (defined as concentric LV remodeling, concentric LVH, or eccentric
273 LVH as determined by LVMI and RWT) even after adjusting for important confounders. These
274 findings are of clinical significance because abnormal LV geometry, particularly LVH, is an
275 independent predictor of adverse CVD events including heart failure, ischemic heart disease,
276 and sudden cardiac death.³²⁻³⁴ We also found an association between de novo HDP and
277 abnormal LV diastolic function, which is linked with higher incidence of CVD events in healthy
278 cohorts and is a strong predictor of progression to heart failure with preserved ejection fraction
279 (HFpEF).^{35,36} Further, individual measures of LV geometry (LVMI, LV RWT) that we found to be
280 associated with history of de novo HDP have also been shown to be associated with CVD
281 events. For instance, in the Framingham Heart Study of Offspring cohort among adults free of
282 CVD, each 10 g/m² increment in LVMI was associated with 33% increased risk of CVD and
283 each 0.1 unit in LV RWT was associated with 59% increased risk of CVD.³⁷

284

285 Further, this is the first known study to identify evidence of HDP associated with decrements in
286 LV systolic function. The finding of slightly lower LV ejection fraction despite greater concentric
287 remodeling and a trend towards greater stroke volume suggests a type of contractile inefficiency
288 that is not typically seen in the setting of current hypertension alone, suggesting a
289 pathophysiology distinct form of hypertensive heart disease. These findings and the diastolic
290 dysfunction exhibited by these mothers all suggest a pre- HFpEF remodeling phenotype,
291 supported by the excess risk of HFpEF in women with preeclampsia, that warrants further
292 investigation.^{38,39}

293
294 Hypertension results in chronic central pressure overload and myocardial ischemia that leads to
295 the development of LVH and heart failure. Therefore, we evaluated the extent to which current
296 hypertension mediated the association between history of de novo HDP and measures of LV
297 structure and function. Hypertension is associated with significantly higher rates of concentric
298 LVH and is a strong independent predictor of LV diastolic dysfunction, but the association with
299 eccentric LVH and LV systolic dysfunction is less robust.^{40,41} This helps explain why
300 hypertension was a moderate mediator in the association between HDP and concentric LVH
301 and LV diastolic dysfunction but a weaker mediator of LV ejection fraction (a measure of LV
302 systolic function). Our results are consistent with large epidemiologic data indicating that the
303 association of HDP with later-life CVD is only partially mediated by current hypertension.⁵ These
304 findings provide insights into HDP as a potential novel mechanism to explain the
305 disproportionally higher risk of heart failure in women with a history of HDP.^{42,43}

306
307 The mechanisms by which HDP may lead to abnormalities in cardiac structure and function
308 beyond the effects of current hypertension remain to be elucidated.⁴⁴ Diabetes was found to be
309 higher in women with history of de novo HDP and although we included diabetes in our adjusted
310 models it may have contributed to some of our findings. In fact, glucose intolerance, insulin

311 resistance, and diabetes have been shown to be associated with increased LV mass and wall
312 thickness and reduced end-diastolic volume, stroke volume, and ejection fraction.⁴⁵⁻⁴⁷ Further,
313 endothelial dysfunction is a hallmark of the pathophysiology underlying preeclampsia and some
314 studies suggest this can persist after delivery.^{48,49} Activation of pathways involving the
315 antiangiogenic soluble fms-like tyrosine kinase 1 (sFlt-1) in preeclampsia, which can remain at
316 least modestly elevated postpartum, can contribute to endothelial dysfunction and deranged
317 lipid metabolism.⁵⁰⁻⁵² Dysregulations of the renin-angiotensin system may also contribute to
318 persistent postpartum cardiac abnormalities. Additionally, shared upstream factors such as CV
319 risk factors and/or genetics may predispose women to both HDPs and later in life pathological
320 LV remodeling and function. Further investigations are needed to identify the potential
321 mechanisms contributing to cardiac abnormalities and how these may be different by race and
322 ethnicity.

323

324 **Study Limitations**

325 Several limitations of our study merit consideration. The cross-sectional design of our study
326 precludes inference of causality, although timing of reported prior HDP consistently preceded
327 timing of assessed cardiac traits. Prior HDP status was based on self-report, which is subject to
328 recall bias and limits precision with respect to subtypes of HDP; nonetheless, self-report has
329 been evaluated as valid and thus applied in the vast majority of cohort studies on HDP.^{53,54} Data
330 on severity of preeclampsia, number of pregnancies complicated by HDP, time period between
331 HDP pregnancy and echocardiography, and length of postpartum hypertension is not available.
332 Additionally, multiple echocardiographic measures were analyzed, which can lead to heightened
333 Type 1 error rate. Despite these limitations, our study offered several strengths including
334 analyses from the largest study to date investigating the relations of prior HDP with cardiac traits
335 in Hispanic/Latina women who represent a demographically important yet historically
336 understudied population. In addition, all cardiac traits were assessed from echocardiographic

337 protocols that involved standardized image acquisition and centralized measures performed at a
338 core center with high inter- and intra-reader reproducibility and BP obtained in a standardized
339 method.

340

341 **Conclusions**

342 In summary, we found in a large cohort of previously pregnant Hispanic/Latina women that
343 those with history of de novo HDP had detectable and measurable pathological alterations in
344 cardiac structure and systolic and diastolic dysfunction. Our findings suggest that women with
345 prior HDP have pathophysiologic cardiac sequelae decades later, that likely play a role in
346 modulating long-term CV risk. Notwithstanding the need for further investigations into the
347 mechanisms driving HDP pathophysiology, our findings highlight the potential importance of
348 targeted surveillance and interventions aimed at preventing later-life CVD events in these at-risk
349 understudied women.

350

351 **Perspectives**

352 Hispanic/Latina women are disproportionately affected by HDP, yet very little is known on how
353 HDP affects cardiac structure and function in this growing population in the U.S. In this study of
354 a diverse cohort of Hispanic/Latina women, those with history of de novo HDP had higher rates
355 of abnormal LV geometry, and alterations in LV geometry (LVMI, RWT) and function (LVEF,
356 diastolic dysfunction), known predictors of CV events and mortality. Notably, these findings
357 appear to be in part mediated by current hypertension – underscoring the importance of
358 screening for and managing hypertension in this cohort. Hypertension alone did not account for
359 all the associations between history of de novo HDP and morphologic and functional cardiac
360 alterations. With the higher rates of heart failure, particularly HFpEF, in women and the
361 alterations in cardiac structure and function identified in this study we hypothesize HDP may be
362 a sex-specific risk factor that warrants further investigation.

363 **Acknowledgements:**

364 The authors thank the participants and staff of HCHS/SOL for their important contributions to
365 this research. The views expressed in this manuscript are those of the authors and do not
366 necessarily represent the views of the National Heart, Lung, and Blood Institute; the National
367 Institutes of Health; or the U.S. Department of Health and Human Services.

368

369 **Sources of Funding:**

370 The HCHS/SOL study is a collaborative study supported by National Heart, Lung, and Blood
371 Institute (NHLBI) contracts N01-HC65233, N01-HC65234, N01-HC65235, N01-HC65236, and
372 N01-HC65237. The following institutes, centers, or offices contribute to the HCHS/SOL through
373 a transfer of funds to the NHLBI: National Center on Minority Health and Health Disparities, the
374 National Institute on Deafness and Other Communications Disorders, the National Institute of
375 Dental and Craniofacial Research, the National Institute of Diabetes and Digestive and Kidney
376 Diseases, the National Institute of Neurological Disorders and Stroke, and the Office of Dietary
377 Supplements. The authors report the following additional sources of funding: NIH K23-
378 HL136853, NIH K23-HL151867, Erika J. Glazer Women's Heart Research Initiative, and the
379 Barbra Streisand Women's Cardiovascular Research and Education Program.

380

381 **Disclosures**

382 The authors report no relevant disclosures.

383

384

385 REFERENCES

- 386 1. Freaney PM, Harrington K, Molsberry R, Perak AM, Wang MC, Grobman W, Greenland
387 P, Allen NB, Capewell S, O'Flaherty M, et al. Temporal Trends in Adverse Pregnancy
388 Outcomes in Birthing Individuals Aged 15 to 44 Years in the United States, 2007 to
389 2019. *J Am Heart Assoc.* 2022;11:e025050. doi: 10.1161/JAHA.121.025050
- 390 2. Shah NS, Harrington KA, Huang X, Cameron NA, Yee LM, Khan SS. Trends in De
391 Novo Hypertensive Disorders of Pregnancy Among Asian and Hispanic Population
392 Subgroups in the United States, 2011 to 2019. *JAMA Cardiol.* 2022;7:742-746. doi:
393 10.1001/jamacardio.2022.1378
- 394 3. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of
395 cardiovascular disease and cancer in later life: systematic review and meta-analysis. *BMJ.*
396 2007;335:974. doi: 10.1136/bmj.39335.385301.BE
- 397 4. Garovic VD, White WM, Vaughan L, Saiki M, Parashuram S, Garcia-Valencia O,
398 Weissgerber TL, Milic N, Weaver A, Mielke MM. Incidence and Long-Term Outcomes
399 of Hypertensive Disorders of Pregnancy. *J Am Coll Cardiol.* 2020;75:2323-2334. doi:
400 10.1016/j.jacc.2020.03.028
- 401 5. Honigberg MC, Zekavat SM, Aragam K, Klarin D, Bhatt DL, Scott NS, Peloso GM,
402 Natarajan P. Long-Term Cardiovascular Risk in Women With Hypertension During
403 Pregnancy. *J Am Coll Cardiol.* 2019;74:2743-2754. doi: 10.1016/j.jacc.2019.09.052
- 404 6. Torosyan N, Aziz D, Quesada O. Long-term sequelae of adverse pregnancy outcomes.
405 *Maturitas.* 2022;165:1-7. doi: 10.1016/j.maturitas.2022.06.012
- 406 7. Wu P, Haththotuwa R, Kwok CS, Babu A, Kotronias RA, Rushton C, Zaman A, Fryer
407 AA, Kadam U, Chew-Graham CA, et al. Preeclampsia and Future Cardiovascular Health:
408 A Systematic Review and Meta-Analysis. *Circ Cardiovasc Qual Outcomes.* 2017;10. doi:
409 10.1161/CIRCOUTCOMES.116.003497
- 410 8. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ,
411 Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, et al. 2019 ACC/AHA
412 Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the
413 American College of Cardiology/American Heart Association Task Force on Clinical
414 Practice Guidelines. *Circulation.* 2019;140:e596-e646. doi:
415 10.1161/CIR.0000000000000678
- 416 9. Castleman JS, Ganapathy R, Taki F, Lip GY, Steeds RP, Kotecha D. Echocardiographic
417 Structure and Function in Hypertensive Disorders of Pregnancy: A Systematic Review.
418 *Circ Cardiovasc Imaging.* 2016;9. doi: 10.1161/CIRCIMAGING.116.004888
- 419 10. Melchiorre K, Sutherland GR, Baltabaeva A, Liberati M, Thilaganathan B. Maternal
420 cardiac dysfunction and remodeling in women with preeclampsia at term. *Hypertension.*
421 2011;57:85-93. doi: 10.1161/HYPERTENSIONAHA.110.162321
- 422 11. Scantlebury DC, Kane GC, Wiste HJ, Bailey KR, Turner ST, Arnett DK, Devereux RB,
423 Mosley TH, Jr., Hunt SC, Weder AB, et al. Left ventricular hypertrophy after
424 hypertensive pregnancy disorders. *Heart.* 2015;101:1584-1590. doi: 10.1136/heartjnl-
425 2015-308098
- 426 12. Vaught AJ, Kovell LC, Szymanski LM, Mayer SA, Seifert SM, Vaidya D, Murphy JD,
427 Argani C, O'Kelly A, York S, et al. Acute Cardiac Effects of Severe Pre-Eclampsia. *J Am*
428 *Coll Cardiol.* 2018;72:1-11. doi: 10.1016/j.jacc.2018.04.048
- 429 13. Levine LD, Ky B, Chirinos JA, Koshinski J, Arany Z, Riis V, Elovitz MA, Koelper N,
430 Lewey J. Prospective Evaluation of Cardiovascular Risk 10 Years After a Hypertensive

- 431 Disorder of Pregnancy. *J Am Coll Cardiol*. 2022;79:2401-2411. doi:
432 10.1016/j.jacc.2022.03.383
- 433 14. Countouris ME, Villanueva FS, Berlacher KL, Cavalcante JL, Parks WT, Catov JM.
434 Association of Hypertensive Disorders of Pregnancy With Left Ventricular Remodeling
435 Later in Life. *J Am Coll Cardiol*. 2021;77:1057-1068. doi: 10.1016/j.jacc.2020.12.051
- 436 15. Behrens I, Basit S, Melbye M, Lykke JA, Wohlfahrt J, Bundgaard H, Thilaganathan B,
437 Boyd HA. Risk of post-pregnancy hypertension in women with a history of hypertensive
438 disorders of pregnancy: nationwide cohort study. *BMJ*. 2017;358:j3078. doi:
439 10.1136/bmj.j3078
- 440 16. Benschop L, Duvekot JJ, Versmissen J, van Broekhoven V, Steegers EAP, Roeters van
441 Lennep JE. Blood Pressure Profile 1 Year After Severe Preeclampsia. *Hypertension*.
442 2018;71:491-498. doi: 10.1161/HYPERTENSIONAHA.117.10338
- 443 17. Podymow T, August P. Postpartum course of gestational hypertension and preeclampsia.
444 *Hypertens Pregnancy*. 2010;29:294-300. doi: 10.3109/10641950902777747
- 445 18. Conomos MP, Laurie CA, Stilp AM, Gogarten SM, McHugh CP, Nelson SC, Sofer T,
446 Fernandez-Rhodes L, Justice AE, Graff M, et al. Genetic Diversity and Association
447 Studies in US Hispanic/Latino Populations: Applications in the Hispanic Community
448 Health Study/Study of Latinos. *Am J Hum Genet*. 2016;98:165-184. doi:
449 10.1016/j.ajhg.2015.12.001
- 450 19. Lavange LM, Kalsbeek WD, Sorlie PD, Aviles-Santa LM, Kaplan RC, Barnhart J, Liu K,
451 Giachello A, Lee DJ, Ryan J, et al. Sample design and cohort selection in the Hispanic
452 Community Health Study/Study of Latinos. *Ann Epidemiol*. 2010;20:642-649. doi:
453 10.1016/j.annepidem.2010.05.006
- 454 20. Sorlie PD, Aviles-Santa LM, Wassertheil-Smoller S, Kaplan RC, Daviglius ML,
455 Giachello AL, Schneiderman N, Raij L, Talavera G, Allison M, et al. Design and
456 implementation of the Hispanic Community Health Study/Study of Latinos. *Ann*
457 *Epidemiol*. 2010;20:629-641. doi: 10.1016/j.annepidem.2010.03.015
- 458 21. Aggarwal SR, Herrington DM, Vladutiu CJ, Newman JC, Swett K, Gonzalez F, Kizer JR,
459 Kominiarek MA, Tabb KM, Gallo LC, et al. Higher number of live births is associated
460 with left ventricular diastolic dysfunction and adverse cardiac remodelling among US
461 Hispanic/Latina women: results from the Echocardiographic Study of Latinos. *Open*
462 *Heart*. 2017;4:e000530. doi: 10.1136/openhrt-2016-000530
- 463 22. Vladutiu CJ, Siega-Riz AM, Sotres-Alvarez D, Stuebe AM, Ni A, Tabb KM, Gallo LC,
464 Potter JE, Heiss G. Parity and Components of the Metabolic Syndrome Among US
465 Hispanic/Latina Women. *Circulation: Cardiovascular Quality and Outcomes*.
466 2016;9:S62-S69. doi: doi:10.1161/CIRCOUTCOMES.115.002464
- 467 23. Shah AM, Cheng S, Skali H, Wu J, Mangion JR, Kitzman D, Matsushita K, Konety S,
468 Butler KR, Fox ER, et al. Rationale and design of a multicenter echocardiographic study
469 to assess the relationship between cardiac structure and function and heart failure risk in a
470 biracial cohort of community-dwelling elderly persons: the Atherosclerosis Risk in
471 Communities study. *Circ Cardiovasc Imaging*. 2014;7:173-181. doi:
472 10.1161/circimaging.113.000736
- 473 24. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA,
474 Foster E, Goldstein SA, Kuznetsova T, et al. Recommendations for cardiac chamber
475 quantification by echocardiography in adults: an update from the American Society of

- 476 Echocardiography and the European Association of Cardiovascular Imaging. *European*
477 *heart journal cardiovascular Imaging*. 2015;16:233-270. doi: 10.1093/ehjci/jev014
- 478 25. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, 3rd, Dokainish H, Edvardsen T,
479 Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, et al. Recommendations for the
480 Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from
481 the American Society of Echocardiography and the European Association
482 of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2016;29:277-314. doi:
483 10.1016/j.echo.2016.01.011
- 484 26. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD,
485 Flachskampf FA, Pellikka PA, Evangelista A. Recommendations for the evaluation of
486 left ventricular diastolic function by echocardiography. *J Am Soc Echocardiogr*.
487 2009;22:107-133. doi: 10.1016/j.echo.2008.11.023
- 488 27. Redfield MM, Jacobsen SJ, Burnett JC, Jr., Mahoney DW, Bailey KR, Rodeheffer RJ.
489 Burden of systolic and diastolic ventricular dysfunction in the community: appreciating
490 the scope of the heart failure epidemic. *Jama*. 2003;289:194-202. doi:
491 10.1001/jama.289.2.194
- 492 28. Mehta H, Armstrong A, Swett K, Shah SJ, Allison MA, Hurwitz B, Bangdiwala S,
493 Dadhania R, Kitzman DW, Arguelles W, et al. Burden of Systolic and Diastolic Left
494 Ventricular Dysfunction Among Hispanics in the United States: Insights From the
495 Echocardiographic Study of Latinos. *Circ Heart Fail*. 2016;9:e002733. doi:
496 10.1161/circheartfailure.115.002733
- 497 29. Ford ND, Cox S, Ko JY, Ouyang L, Romero L, Colarusso T, Ferre CD, Kroelinger CD,
498 Hayes DK, Barfield WD. Hypertensive Disorders in Pregnancy and Mortality at Delivery
499 Hospitalization - United States, 2017-2019. *MMWR Morb Mortal Wkly Rep*.
500 2022;71:585-591. doi: 10.15585/mmwr.mm7117a1
- 501 30. Boardman H, Lamata P, Lazdam M, Verburg A, Siepmann T, Upton R, Bilderbeck A,
502 Dore R, Smedley C, Kenworthy Y, et al. Variations in Cardiovascular Structure,
503 Function, and Geometry in Midlife Associated With a History of Hypertensive
504 Pregnancy. *Hypertension*. 2020;75:1542-1550. doi:
505 10.1161/HYPERTENSIONAHA.119.14530
- 506 31. Bokslag A, Franssen C, Alma LJ, Kovacevic I, Kesteren FV, Teunissen PW, Kamp O,
507 Ganzevoort W, Hordijk PL, Groot CJM, et al. Early-onset preeclampsia predisposes to
508 preclinical diastolic left ventricular dysfunction in the fifth decade of life: An
509 observational study. *PLoS One*. 2018;13:e0198908. doi: 10.1371/journal.pone.0198908
- 510 32. Bluemke DA, Kronmal RA, Lima JA, Liu K, Olson J, Burke GL, Folsom AR. The
511 relationship of left ventricular mass and geometry to incident cardiovascular events: the
512 MESA (Multi-Ethnic Study of Atherosclerosis) study. *J Am Coll Cardiol*. 2008;52:2148-
513 2155. doi: 10.1016/j.jacc.2008.09.014
- 514 33. Cheng S, Fernandes VR, Bluemke DA, McClelland RL, Kronmal RA, Lima JA. Age-
515 related left ventricular remodeling and associated risk for cardiovascular outcomes: the
516 Multi-Ethnic Study of Atherosclerosis. *Circ Cardiovasc Imaging*. 2009;2:191-198. doi:
517 10.1161/CIRCIMAGING.108.819938
- 518 34. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of
519 echocardiographically determined left ventricular mass in the Framingham Heart Study.
520 *N Engl J Med*. 1990;322:1561-1566. doi: 10.1056/NEJM199005313222203

- 521 35. Nayor M, Cooper LL, Enserro DM, Xanthakis V, Larson MG, Benjamin EJ, Aragam J,
522 Mitchell GF, Vasan RS. Left Ventricular Diastolic Dysfunction in the Community:
523 Impact of Diagnostic Criteria on the Burden, Correlates, and Prognosis. *J Am Heart*
524 *Assoc.* 2018;7. doi: 10.1161/JAHA.117.008291
- 525 36. Kane GC, Karon BL, Mahoney DW, Redfield MM, Roger VL, Burnett JC, Jr., Jacobsen
526 SJ, Rodeheffer RJ. Progression of left ventricular diastolic dysfunction and risk of heart
527 failure. *JAMA.* 2011;306:856-863. doi: 10.1001/jama.2011.1201
- 528 37. Tsao CW, Gona PN, Salton CJ, Chuang ML, Levy D, Manning WJ, O'Donnell CJ. Left
529 Ventricular Structure and Risk of Cardiovascular Events: A Framingham Heart Study
530 Cardiac Magnetic Resonance Study. *J Am Heart Assoc.* 2015;4:e002188. doi:
531 10.1161/JAHA.115.002188
- 532 38. Williams D, Stout MJ, Rosenbloom JI, Olsen MA, Joynt Maddox KE, Deych E, Davila-
533 Roman VG, Lindley KJ. Preeclampsia Predicts Risk of Hospitalization for Heart Failure
534 With Preserved Ejection Fraction. *J Am Coll Cardiol.* 2021;78:2281-2290. doi:
535 10.1016/j.jacc.2021.09.1360
- 536 39. Hansen AL, Sondergaard MM, Hlatky MA, Vittinghof E, Nah G, Stefanick ML, Manson
537 JE, Farland LV, Wells GL, Mongraw-Chaffin M, et al. Adverse Pregnancy Outcomes and
538 Incident Heart Failure in the Women's Health Initiative. *JAMA Netw Open.*
539 2021;4:e2138071. doi: 10.1001/jamanetworkopen.2021.38071
- 540 40. Yun M, Li S, Yan Y, Sun D, Guo Y, Fernandez C, Bazzano L, He J, Zhang T, Chen W.
541 Blood Pressure and Left Ventricular Geometric Changes: A Directionality Analysis.
542 *Hypertension.* 2021;78:1259-1266. doi: 10.1161/HYPERTENSIONAHA.121.18035
- 543 41. Verdecchia P, Angeli F, Gattobigio R, Sardone M, Porcellati C. Asymptomatic left
544 ventricular systolic dysfunction in essential hypertension: prevalence, determinants, and
545 prognostic value. *Hypertension.* 2005;45:412-418. doi:
546 10.1161/01.HYP.0000154822.37141.f6
- 547 42. Behrens I, Basit S, Lykke JA, Ranthe MF, Wohlfahrt J, Bundgaard H, Melbye M, Boyd
548 HA. Association Between Hypertensive Disorders of Pregnancy and Later Risk of
549 Cardiomyopathy. *JAMA.* 2016;315:1026-1033. doi: 10.1001/jama.2016.1869
- 550 43. Honigberg MC, Riise HKR, Daltveit AK, Tell GS, Sulo G, Igland J, Klungsoyr K, Scott
551 NS, Wood MJ, Natarajan P, et al. Heart Failure in Women With Hypertensive Disorders
552 of Pregnancy: Insights From the Cardiovascular Disease in Norway Project.
553 *Hypertension.* 2020;76:1506-1513. doi: 10.1161/HYPERTENSIONAHA.120.15654
- 554 44. Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: Pathophysiology,
555 Challenges, and Perspectives. *Circ Res.* 2019;124:1094-1112. doi:
556 10.1161/CIRCRESAHA.118.313276
- 557 45. Kishi S, Gidding SS, Reis JP, Colangelo LA, Venkatesh BA, Armstrong AC, Isogawa A,
558 Lewis CE, Wu C, Jacobs DR, Jr., et al. Association of Insulin Resistance and Glycemic
559 Metabolic Abnormalities With LV Structure and Function in Middle Age: The CARDIA
560 Study. *JACC Cardiovasc Imaging.* 2017;10:105-114. doi: 10.1016/j.jcmg.2016.02.033
- 561 46. Rutter MK, Parise H, Benjamin EJ, Levy D, Larson MG, Meigs JB, Nesto RW, Wilson
562 PW, Vasan RS. Impact of glucose intolerance and insulin resistance on cardiac structure
563 and function: sex-related differences in the Framingham Heart Study. *Circulation.*
564 2003;107:448-454. doi: 10.1161/01.cir.0000045671.62860.98
- 565 47. Lv J, Liu Y, Yan Y, Sun D, Fan L, Guo Y, Fernandez C, Bazzano L, He J, Li S, et al.
566 Relationship Between Left Ventricular Hypertrophy and Diabetes Is Likely Bidirectional:

- 567 A Temporality Analysis. *J Am Heart Assoc.* 2023;12:e028219. doi:
568 10.1161/JAHA.122.028219
- 569 48. Savvidou MD, Hingorani AD, Tsikas D, Frolich JC, Vallance P, Nicolaides KH.
570 Endothelial dysfunction and raised plasma concentrations of asymmetric
571 dimethylarginine in pregnant women who subsequently develop pre-eclampsia. *Lancet.*
572 2003;361:1511-1517. doi: 10.1016/S0140-6736(03)13177-7
- 573 49. Germain AM, Romanik MC, Guerra I, Solari S, Reyes MS, Johnson RJ, Price K,
574 Karumanchi SA, Valdes G. Endothelial dysfunction: a link among preeclampsia,
575 recurrent pregnancy loss, and future cardiovascular events? *Hypertension.* 2007;49:90-
576 95. doi: 10.1161/01.HYP.0000251522.18094.d4
- 577 50. Wolf M, Hubel CA, Lam C, Sampson M, Ecker JL, Ness RB, Rajakumar A, Daftary A,
578 Shakir AS, Seely EW, et al. Preeclampsia and future cardiovascular disease: potential
579 role of altered angiogenesis and insulin resistance. *J Clin Endocrinol Metab.*
580 2004;89:6239-6243. doi: 10.1210/jc.2004-0548
- 581 51. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP,
582 Sellke FW, Stillman IE, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1)
583 may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.
584 *J Clin Invest.* 2003;111:649-658. doi: 10.1172/JCI17189
- 585 52. Bytautiene E, Bulayeva N, Bhat G, Li L, Rosenblatt KP, Saade GR. Long-term
586 alterations in maternal plasma proteome after sFlt1-induced preeclampsia in mice. *Am J*
587 *Obstet Gynecol.* 2013;208:388.e381-388.e310. doi: 10.1016/j.ajog.2013.01.042
- 588 53. Stuart JJ, Bairey Merz CN, Berga SL, Miller VM, Ouyang P, Shufelt CL, Steiner M,
589 Wenger NK, Rich-Edwards JW. Maternal recall of hypertensive disorders in pregnancy:
590 a systematic review. *J Womens Health (Larchmt).* 2013;22:37-47. doi:
591 10.1089/jwh.2012.3740
- 592 54. Carter EB, Stuart JJ, Farland LV, Rich-Edwards JW, Zera CA, McElrath TF, Seely EW.
593 Pregnancy Complications as Markers for Subsequent Maternal Cardiovascular Disease:
594 Validation of a Maternal Recall Questionnaire. *J Womens Health (Larchmt).*
595 2015;24:702-712. doi: 10.1089/jwh.2014.4953
596

597 **Pathophysiological Novelty and Relevance**

598 **What is new?**

- 599 • First study to evaluate the cardiac sequelae of de novo hypertensive disorder of
600 pregnancy (HDP) in a cohort of 5,168 Hispanic/Latina women.

601 **What is relevant?**

- 602 • Women with de novo HDP had detectable and measurable subclinical alterations in
603 cardiac structure and both systolic and diastolic dysfunction, above and beyond the
604 effects of current hypertension.

605 **Clinical/Pathophysiologic Implications?**

- 606 • Our findings suggest that women with de novo HDP have pathophysiologic cardiac
607 sequelae decades later that likely play a role in modulating long-term cardiovascular risk
608 in women.

609

610 **Figure Legend**

611 **Figure 1.** Sampling Strategy and Study Design.

612 **Central Illustration.** Proportion of association between hypertensive disorders of pregnancy
613 and measures of left ventricular structure and function mediated by current hypertension.

614 Figure created using BioRender.

615

616

617

Table 1. Demographics and Clinical Characteristics by De Novo Hypertensive Disorders of Pregnancy History

Characteristics at Visit 2	Overall N=5168	De Novo Hypertensive Disorders of Pregnancy History		P value	Adjusted P value
		No N=4444	Yes N=724		
Demographics					
Age, years, mean (SD)	58.7 (9.7)	59.2 (9.7)	56.3 (8.8)	<0.001	<0.001
Hispanic/Latino Background, %				0.07	0.68
Dominican	11	11	13		
Central/South American	12	12	12		
Cuban	22	22	23		
Mexican	34	36	28		
Puerto-Rican	18	17	21		
Other or more than one heritage	3	2	4		
Participant's Field Center, %				0.1	0.86
Bronx	29	28	33		
Chicago	13	13	11		
Miami	32	32	34		
San Diego	26	27	23		
Years living in US, years, mean (SD)	29.3 (16.6)	29.3 (16.5)	28.9 (16.7)	0.71	1.0
Annual Family income ≥\$30,000, %	62	62	62	1.0	1.0
Health Insurance Coverage, %	81	81	82	0.49	1.0
Clinical Characteristics					
Blood pressure based on ACC/AHA, %				<0.001	<0.001
Normal	27	30	18		
Elevated BP	9	10	6		
Stage 1 Hypertension	43	41	58		
Stage 2 Hypertension	11	11	10		
Antihypertensive therapy, %	43	41	58	<0.001	<0.001

Diabetes Mellitus, %	31	30	39	<0.001	<0.001
Dyslipidemia, %	30	29	35	0.021	0.27
Metabolic Syndrome, %	53	51	63	<0.001	<0.001
Current smoker, %	13	13	14	0.66	1.0
Number of Pregnancy, mean (SD)	4 (2)	4 (2)	4 (2)	0.6	1.0
HDP Type, %					
Gestational Hypertension	61	-	61		
Preeclampsia	30	-	30		
Eclampsia	9	-	9		
Clinical Measures					
Systolic blood pressure, mmHg, mean (SD)	127 (20)	127 (20)	129 (19)	0.047	0.51
Diastolic blood pressure, mmHg, mean (SD)	73 (11)	72 (10)	76 (12)	<0.001	<0.001
Body Mass Index, kg/m ² , mean (SD)	31 (6)	30 (6)	32 (7)	<0.001	<0.001
Cholesterol, Total, mg/dL, mean (SD)	201 (40)	200 (40)	203 (41)	0.31	1.0
LDL cholesterol, mg/dL, mean (SD)	121 (36)	121 (36)	121 (37)	0.76	1.0
HDL cholesterol, mg/dL, mean (SD)	54 (15)	55 (15)	53 (15)	0.032	0.38
Triglycerides, mg/dL, mean (SD)	130 (80)	127 (72)	144 (116)	0.003	0.049
Urine Albumin/creatinine ratio, mean (SD)	46 (330)	40 (318)	77 (404)	0.12	0.93

Table 2. Differences in Measures of Left Ventricle Structure and Function by De Novo Hypertensive Disorders of Pregnancy

History

Echocardiographic Measures	Overall	De Novo Hypertensive Disorders of Pregnancy History		P value	Adjusted P value
		No	Yes		
Continuous Measures					
LV ejection fraction, %	71.55 (4.50)	71.72 (4.44)	70.68 (4.76)	<0.001	0.005
LV stroke volume, mL	60.35 (11.43)	59.86 (11.15)	62.65 (12.42)	<0.001	0.003
LV mass index, g/m ²	76.09 (16.57)	75.61 (15.90)	78.40 (19.35)	0.015	0.12
LV end-diastolic diameter, cm	4.24 (0.37)	4.23 (0.36)	4.26 (0.41)	0.24	1.0
LVMI/EDV ratio	0.92 (0.24)	0.93 (0.23)	0.90 (0.25)	0.13	0.79
LV relative wall thickness, cm	0.44 (0.07)	0.44 (0.07)	0.46 (0.07)	0.001	0.009
PTRV, cm/s	220.48 (30.04)	219.72 (30.36)	224.90 (27.94)	0.045	0.32
Lateral E/e' ratio	8.8 (3.4)	8.7 (3.4)	8.9 (3.4)	0.38	1.0
Categorical Measures					
Concentric LV remodeling, %	46	45	49	0.26	1.0
Concentric LVH, %	9	8	13	0.005	0.04
Eccentric LVH, %	3	2	5	0.2	1.0
Abnormal LV geometry, %	57	56	66	0.002	0.017
Abnormal LV diastolic function, %	35	35	35	0.98	1.0

LV, left ventricle; LVMI, LV mass index; EDV, end-diastolic volume; PTRG, Peak tricuspid regurgitation velocity; LVH, left ventricular hypertrophy

Table 3. Associations between De Novo Hypertensive Disorders of Pregnancy History and Measures of Left Ventricle Structure and Function.

Echocardiographic Measures	Model 1		Model 2		Model 3	
	Coefficient (95% CI)	P value	Coefficient (95% CI)	P value	Coefficient (95% CI)	P value
Continuous Measures						
LV ejection fraction, %	-0.90 (-1.45, -0.04)	0.001	-0.75 (-1.30, -0.21)	0.007	-0.66 (-1.21, -0.11)	0.02
LV stroke volume, mL	1.72 (0.32, 3.12)	0.016	0.94 (-0.41, 2.29)	0.17	0.32 (-0.96, 1.61)	0.62
LV mass index, g/m ²	3.70 (1.46, 5.94)	0.001	1.57 (-0.50, 3.64)	0.14	1.05 (-1.01, 3.10)	0.32
LV end-diastolic diameter, cm	0.01 (-0.49, 0.52)	0.96	-0.12 (-0.62, 0.38)	0.65	-0.29 (-0.75, 0.18)	0.23
LVMI/EDV ratio	0.01 (-0.03, 0.04)	0.72	-0.01 (-0.04, 0.03)	0.72	0 (-0.04, 0.03)	0.92
LV relative wall thickness, cm	0.22 (0.13, 0.31)	<0.001	0.14 (0.05, 0.23)	0.003	0.09 (0.00, 0.18)	0.039
PTRV, cm/s	7.37 (2.50, 12.25)	0.003	4.0 (-0.92, 8.92)	0.11	2.22 (-2.65, 7.09)	0.37
Lateral E/e' ratio	0.58 (0.19, 0.96)	0.004	0.19 (-0.19, 0.58)	0.33	0 (-0.37, 0.38)	0.10
Categorical Measures						
Concentric LV remodeling, %	1.33 (1.01, 1.75)	0.046	1.25 (0.94, 1.67)	0.12	1.16 (0.87, 1.55)	0.31
Concentric LVH, %	1.92 (1.32, 2.79)	0.001	1.45 (0.97, 2.16)	0.07	1.30 (0.85, 1.99)	0.22
Eccentric LVH, %	1.60 (0.80, 3.21)	0.19	1.32 (0.64, 2.75)	0.45	1.38 (0.63, 3.00)	0.42
Abnormal LV geometry, %	1.86 (1.39, 2.49)	<0.001	1.51 (1.12, 2.03)	0.007	1.39 (1.02, 1.89)	0.038
Abnormal LV diastolic function, %	1.52 (1.13, 2.05)	0.006	1.14 (0.83, 1.57)	0.43	1.02 (0.73, 1.42)	0.90

LV, left ventricle; LVMI, LV mass index; EDV, end-diastolic volume; PTRG, Peak tricuspid regurgitation velocity; LVH, left ventricular hypertrophy

Model 1 is adjusted for age, field center, Hispanic background; Model 2 is adjusted for all variables in Model 1, in addition to systolic blood pressure and antihypertensive therapy at Visit 2; Model 3 is adjusted for all variables in Model 2, in addition to diabetes status, smoking, total cholesterol HDL ratio, number of pregnancies, BMI, urine albumin-to-creatinine ratio

Table 4. Causal Mediation Analysis to Assess Mediation Effect of Current Hypertension for Observed Association Between De Novo Hypertensive Disorders of Pregnancy and Measures of Left Ventricle Structure and Function.

Echocardiographic Measures	Proportion of Association with HDP Mediated by Current Hypertension (95% CI)	P value
LV ejection fraction	0.09 (0.03, 0.45)	0.01
LV relative wall thickness	0.28 (0.16, 0.51)	<0.001
Concentric LVH	0.31 (0.19, 0.86)	<0.001
Abnormal LV geometry	0.14 (0.12, 0.48)	<0.001
Abnormal LV diastolic function	0.58 (0.26, 0.79)	0.006

Models are adjusted for age, field center, Hispanic/Latino background, and current hypertension (defined as BP >140/90 or antihypertensive therapy).

Supplemental Table 1. Differences in Measures of Left Ventricle Structure and Function by Type of Hypertensive Disorders of Pregnancy.

Echocardiographic Measures	De Novo Hypertensive Disorders of Pregnancy History				p-trend
	None	Gestational Hypertension	Preeclampsia	Eclampsia	
Continuous Measures					
LV ejection fraction, %	71.72 (4.44)	70.65 (4.65)	71.22 (4.26)	69.36 (6.23)	<0.001
LV stroke volume, mL	59.86 (11.15)	63.64 (13.03)	61.90 (11.56)	59.34 (10.67)	<0.001
LV mass index, g/m ²	75.61 (15.91)	80.06 (20.75)	75.70 (16.42)	76.86 (18.35)	0.19
LV end-diastolic diameter, cm	4.23 (0.36)	4.28 (0.44)	4.26 (0.35)	4.19 (0.38)	0.60
LVMi/EDV ratio	0.93 (0.23)	0.91 (0.27)	0.89 (0.21)	0.91 (0.20)	0.003
LV relative wall thickness, cm	0.44 (0.07)	0.46 (0.07)	0.44 (0.07)	0.47 (0.09)	<0.001
PTRV, cm/s	219.72 (30.37)	226.58 (29.95)	221.93 (23.70)	222.72 (27.09)	0.12
Lateral E/e' ratio	8.73 (3.38)	9.22 (3.85)	8.41 (2.62)	8.59 (2.73)	0.01
Categorical Measures					
Concentric LV remodeling, %	45.2	50.4	39.6	66.6	0.07
Concentric LVH, %	8.3	16.8	9.7	4.1	0.005
Eccentric LVH, %	2.3	5.1	0.6	4.2	0.99
Abnormal LV geometry, %	55.9	72.2	50.2	74.9	<0.001
Abnormal LV diastolic function, %	35.3	38.7	29.7	32.7	0.38

Supplemental Table 2. Associations between Gestational Hypertension and Preeclampsia and Measures of Left Ventricle Structure and Function.

Echocardiographic Measures	Gestational Hypertension					
	Model 1		Model 2		Model 3	
	Coefficient (95% CI)	P value	Coefficient (95% CI)	P value	Coefficient (95% CI)	P value
Continuous Measures						
LV ejection fraction, %	-0.92 (-1.60, -0.24)	0.008	-0.77 (-1.45, -0.09)	0.027	-0.61 (-1.32, 0.09)	0.09
LV stroke volume, mL	2.82 (0.95, 4.69)	0.003	1.88 (0.11, 3.65)	0.038	1.14 (-0.53, 2.81)	0.18
LV mass index, g/m ²	5.20 (2.00, 8.41)	0.002	2.63 (-0.45, 5.71)	0.09	1.76 (-1.38, 4.90)	0.27
LV end-diastolic diameter, cm	0.17 (-0.57, 0.90)	0.66	0.002 (-0.71, 0.72)	1.0	-0.27 (-0.96, 0.43)	0.45
LVMI/EDV ratio	0.009 (-0.04, 0.06)	0.69	-0.005 (-0.05, 0.04)	0.83	-0.0006 (-0.05, 0.05)	0.98
LV relative wall thickness, cm	0.27 (0.17, 0.38)	<0.001	0.18 (0.07, 0.29)	0.002	0.12 (0.01, 0.23)	0.03
PTRV, cm/s	9.07 (2.79, 15.35)	0.005	4.82 (-1.64, 11.29)	0.14	1.96 (-4.33, 8.26)	0.54
Categorical Measures						
Concentric LV remodeling, %	1.38 (0.97, 1.96)	0.07	1.32 (0.92, 1.90)	0.13	1.23 (0.85, 1.79)	0.27
Concentric LVH, %	2.48 (1.60, 3.87)	<0.001	1.76 (1.09, 2.85)	0.021	1.54 (0.92, 2.58)	0.10
Eccentric LVH, %	2.24 (1.01, 4.98)	0.048	1.80 (0.78, 4.18)	0.17	1.89 (0.74, 4.79)	0.18
Abnormal LV geometry, %	2.44 (1.69, 3.52)	<0.001	1.96 (1.34, 2.86)	<0.001	1.79 (1.19, 2.69)	0.005
Abnormal LV diastolic function, %	1.86 (1.30, 2.66)	<0.001	1.34 (0.92, 1.94)	0.12	1.17 (0.80, 1.71)	0.42
	Preeclampsia					
Echocardiographic Measures	Model 1		Model 2		Model 3	
	Coefficient (95% CI)	P value	Coefficient (95% CI)	P value	Coefficient (95% CI)	P value
Continuous Measures						
LV ejection fraction, %	-0.55 (-1.35, 0.24)	0.17	-0.46 (-1.25, 0.32)	0.25	-0.43 (-1.19, 0.33)	0.27
LV stroke volume, mL	1.11 (-1.01, 3.22)	0.31	0.54 (-1.50, 2.59)	0.60	0.27 (-1.81, 2.34)	0.80
LV mass index, g/m ²	1.33 (-2.18, 4.84)	0.46	-0.34 (-3.37, 2.69)	0.83	-0.22 (-3.18, 2.74)	0.88
LV end-diastolic diameter, cm	-0.03 (-0.78, 0.72)	0.94	-0.11 (-0.84, 0.63)	0.78	-0.15 (-0.82, 0.51)	0.65

LVM/EDV ratio	-0.01 (-0.05, 0.03)	0.56	-0.02 (-0.06, 0.02)	0.27	-0.02 (-0.06, 0.02)	0.37
LV relative wall thickness, cm	0.08 (-0.06, 0.23)	0.24	0.02 (-0.11, 0.15)	0.75	0.008 (-0.12, 0.14)	0.90
PTRV, cm/s	4.40 (-2.73, 11.53)	0.23	1.41 (-5.97, 8.80)	0.71	1.19 (-6.37, 8.75)	0.76
Categorical Measures						
Concentric LV remodeling, %	0.95 (0.58, 1.57)	0.85	0.92 (0.56, 1.53)	0.75	0.86 (0.53, 1.41)	0.56
Concentric LVH, %	1.46 (0.73, 2.93)	0.28	1.14 (0.57, 2.27)	0.71	1.15 (0.57, 2.29)	0.70
Eccentric LVH, %	0.29 (0.06, 1.40)	0.12	0.26 (0.05, 1.28)	0.10	0.27 (0.06, 1.33)	0.11
Abnormal LV geometry, %	1.02 (0.62, 1.68)	0.94	0.87 (0.53, 1.43)	0.57	0.83 (0.50, 1.37)	0.46
Abnormal LV diastolic function, %	1.08 (0.56, 2.07)	0.83	0.88 (0.44, 1.79)	0.73	0.78 (0.37, 1.64)	0.51

